Amazing Medical Tech Firm Getting Noticed
PRED is growing…fast
Predictive’s chairman is also a high-level director at Pfizer
Welcome to the world of regenerative medicine
Good day everyone,
Today we are initiating coverage of Predictive Technology Group, Inc. (OTC: PRED), a company that aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics.
Through its subsidiaries, Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories, the company is focused on endometriosis, scoliosis, degenerative disc disease, and human cell and tissue products.
The subsidiaries use genetic and other information in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases.
Current price $4.50 per share
The company has completed the application and submitted the request to list Predictive on The NASDAQ Exchange. The NASDAQ listing remains subject to the approval of NASDAQ and the satisfaction of all NASDAQ listing standards.
As at the end of Q3 (March 31, 2019), nine-month revenue increased 217% to $30 million with $3.1 million in positive cash flow from operations.
Q3 marks the company’s 10th consecutive quarter of sequential growth in revenue.
PRED seems to have and endless stream of catalysts and milestones fueling its rising stock price and here are a few of them:
Recent Corporate Developments
Integrated the sales and marketing team from FlagshipHealth Group, to support commercial activities for Predictive Biotech and Predictive Laboratories.
Named Sen. Orrin G. Hatch, Ronald Barhorst and Jay M. Moyes to its Board of Directors, expanding its Board to six including four independent directors.
Mr. John E. Sorrentino Chairman of Predictive Technology Group, Inc. is also Vice-President and Chief Operating Officer of Vaccine Research and Development at Pfizer and has vast experience in R&D and clinical laboratory management.
Recent Predictive Laboratories Developments
Completed the acquisition of Taueret Laboratories, LLC, a provider of genetic testing and DNA analysis services through its CAP/CLIA-certified laboratory.
Integrated over $5 million of recently purchased new genomics equipment and supplies into laboratory to expand the technical capabilities and capacities.
Launched ARTguide™ genetic test for reproductive endocrinologists into 14 Key Opinion Leader (KOL) clinics to refine the test ordering and reporting processes.
Presented a poster titled The Genetic Architecture of Endometriosis at the Society for Reproductive Investigation (SRI) meeting.
Recent Predictive Biotech Developments
Reported 10th consecutive quarter-over-quarter revenue growth.
Completed buildout of a new 22,000-square-foot production laboratory and R&D facility meeting good manufacturing Practice (GMP) and Good Tissue Practice (GTP) requirements.
Predictive Biotech’s products are FDA-compliant and sourced from the rich Wharton’s Jelly layer of the umbilical cord and amniotic fluid and amnio tissue from healthy, full-term donors.
Last month signed letter of intent with IQVIA (Formerly Quintiles and IMS) to guide the regulatory FDA process for potential drugs beginning with CoreCyte™ for osteoarthritis (OA) of the knee.
We believe the anticipated uplist to the NASDAQ may send PRED shares soaring. Many institutions and funds are precluded from investments in OTC companies. A NASDAQ listing could open the floodgates for those types of investors.
There is an increasing demand for the company’s human cell and tissue products.
Gross profit margin for first nine months of fiscal 2019 was 63.8%.
Cash provided by operating activities for or the nine months ended March 31, 2019 was $3.1 million.
Senator Orrin Hatch lends a great deal of credibility to the company’s board.
PRED shares have been moving up all year, but have taken a breather in the past few trading days, creating what we feel, could be a buying opportunity.
There are so many catalysts and milestones happening at PRED we’ve dedicated this newsletter primarily to them. Look for our update tomorrow when we discuss Predictive’s amazing technologies, products and future in more detail.
The Traders News Group
TradersNewsSource.com collects your contact information to keep you informed about updates to our web site, newsletters and social channels. All information is kept secure, with only authorized employees having access.
TradersNewsSource.com does from time to time, issue releases to subscribers as “Feature Reports” that may be related to our content partners or advertising sponsors.
We do not sell your contact information to other organizations for commercial purposes. We will not release your email address to anyone, unless you specifically give us permission to do so. Should you decide in the future to unsubscribe from TradersNewsSource.com at any time, simply follow the instructions located at the bottom of each newsletter edition. Your email address will be kept strictly confidential, and will never be shared with anyone for any purpose of any kind.
Regarding Google ads:
ALL STOCKS INVOLVE RISKS AND THE POSSIBILITY OF LOSING ALL OF YOUR INVESTMENT. PLEASE CONSIDER ALL RISKS BEFORE INVESTING.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated fifteen thousand dollars cash via bank wire by Banner Enterprises LLC for this weeks coverage of PRED. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.